TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: LAST REVISED DATE: LAST REVIEWED DATE:

Size: px
Start display at page:

Download "TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: LAST REVISED DATE: LAST REVIEWED DATE:"

Transcription

1 TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: LAST REVISED DATE: LAST REVIEWED DATE: Table of Contents 1. How do I conduct my first few visits with a patient who has chronic, non-cancer pain, and who may desire opioid medications? Pages If a decision is made to start opioid medications, what should I check on before writing the first Rx?... Pages Which opiates should we prescribe in the PCC, and what is the ceiling dose? Page 6 4. Should I prescribe long-acting or short-acting opioids?...page 6 5. Which opiates should I AVOID prescribing in the PCC? Page How should I follow-up with patients, after opiates have been initiated? Pages When should I escalate doses of opiates, and what is the ceiling dose? Page What should I do if I inherit a patient on chronic opiate therapy? Page When should I taper a patient off opioids? Pages How do I taper a patient off opioids? Pages If a patient has had opioids discontinued in the past, when and how should the PCP re-institute chronic opiate therapy? Page Under what circumstances can we give opioid medications for chronic pain during a walk-in visit in the PCC? Page Under what circumstances can we give benzodiazepines in the PCC? Page If a patient is on a opioid that we do not provide in the PCC, how do I convert it to hydrocodone or morphine? Page Who is on the Chronic Pain Task Force? Page How do I approach the patient with a persistently negative UDS?...Page What do I need to know about the UDS? Page Appendix A: Patient-Provider Chronic Pain Management Agreement Pages

2 1. How do I conduct my first visit with a patient who has chronic, non-cancer pain, and who may desire opioid medications? Initiation of opioid pain medications should NOT occur the first time you meet the patient. Use 2-3 successive visits (consider a one-hour visit) to get to know your patient, spending the time to o Develop a trusting relationship o Explore other options for treating chronic pain o Conduct an expanded screen for depressive disorder IF having suicidal ideations or if otherwise severely depressed, then seek immediate MH help Give the option of calling the Georgia Crisis Hotline for mental health emergencies, but also to get linked into routine mental health care: Refer to Dr. Tamara Haynes (board certified in BOTH Internal Medicine and Psychiatry) by sending her an EPIC message with MRN of patient Goal is to control depression BEFORE beginning opioid pain medications Document the pain history, including the impact of pain on the patient s functioning Explain to patient that we may never be able to make their pain go completely away, but we can help them become more functional: o Set specific goals for improving functioning RATHER than improving pain (e.g. I want to be able to walk two blocks to the bus stop. ) Perform and document a directed physical examination targeted to evaluation of the painful areas Review previous diagnostic studies/ interventions Trial of a comprehensive non-opioid medication regimen that includes the following medications BEFORE prescribing opioid medications: Acetaminophen - scheduled daily up to 2grams (or as deemed safe according to patient s chronic conditions) NSAID at anti-inflammatory doses, to be taken with food Also with daily PPI IF at high risk for GI toxicity Avoid in clinically significant renal dysfunction or systolic heart failure TCA low dose (e.g. 25 to 50 mg of Nortriptyline which is slightly less anti-cholinergic than Amitriptyline) AND assuming the patient is not suicidal 2

3 NOTE: explain to patient that the TCA is in the anti-depressant class of medications, HOWEVER it is not being prescribed at anti-depressant dosages, but at smaller dosages proven to help with chronic pain Review the side-effects of TCAs (e.g. drowsiness, dry mouth) Explain that full effect will only be seen IF the patient takes the medication regularly for at least 6-8 weeks Emphasize to patient importance of their active involvement in PT/OT: o PT/OT is more effective than any medication to reach goals o Opioids should NOT be prescribed if PT/OT is not aggressively pursued o Note: PT will dismiss patients from their clinic if several appointments are missed o Activate patient to learn stretches and exercises to be done TID every day on their own Refer to other clinics for pain management, where appropriate: o Steroid injections refer to injection clinic for small joints, refer to pain clinic for back or hip injections o Nerve blocks refer to pain clinic o Counsel patients that opioid medications are NOT prescribed in either of these clinics 3

4 2. If a decision is made to start opioid medications, what should I check on before writing the first Rx? Perform a risk-benefit assessment before initiating any opioid medications. ONLY initiate opioid medications for patients at LOW RISK for opioid abuse. Risk Level Patient Characteristics Low Risk Moderate Risk No history of substance use problem, past or current No contributory family history of substance abuse No major or untreated mental health problems History of substance use problem (treated) Family history of substance abuse Comorbid minor or past major mental health problem High Risk Current substance use problem Active addiction Major untreated mental health problem Educate patients on inability of opioids to cure chronic pain, though they may help improve function Encourage patient to set SPECIFC goals to address function (e.g. I want to walk two blocks to grocery store); assess improvement in function at each subsequent visit Complete an electronic (or written) pain contract, and document in note (see Appendix A) Perform a baseline UDS screening at time of initiation (do NOT initiate opioids if UDS positive for opioids, cocaine, benzodiazepines, amphetamines) Check the GA prescription drug registry ( to ensure patient has not filled any other opioid medications or benzodiazepines (if so, they cannot receive opioids from you). Do NOT initiate and/ or taper off opioids if: o Multiple opioid prescriptions have been filled at less-than-one month intervals o Opioid prescriptions filled at multiple different pharmacies in a short period of time 4

5 o Opioid prescriptions written by doctors other than patient s PCP Ensure the patient has a follow-up appointment with YOU as their PCP at least within the next 90 days, but preferably within 30 days o Okay to overbook if necessary to accomplish this o Consider an extended 60 minute visit, and bill a level 5 visit, in which it is documented that more than 45 minutes was spent in the care of the patient, half of which involved counseling on management of chronic pain. To prevent the patient from running out of medications before their next visit, may prescribe up to (but NO more than) a 90 day supply of medications according to the below federal guidelines: o The 90 day supply must be written as three separate monthly prescriptions with added comments / dates for when to fill each: (e.g. 1 st Rx is written as fill today, 2 nd Rx is written as do not fill until, and 3 rd Rx is written as do not fill until ) o The individual practitioner concludes that providing the patient with multiple prescriptions in this manner is SAFE and does not create an undue risk of diversion or abuse. Document number and frequency of all opioid prescription refills in YOUR clinic note (so it is clear to any other provider how much has been dispensed). Stop tramadol if initiating opiates Wean off benzodiazepines soon, with help of SSRI +/- Hydroxyzine (10-25 mg TID prn) 5

6 3. Which opiates should we prescribe in the PCC, and what is the ceiling dose? We should prescribe hydrocodone or morphine instead of oxycodone. The reason for this is that our UDS is more sensitive for detecting hydrocodone and it s metabolite, hydromorphone. o Short-acting opioids are preferred over long-acting medications. o Long-acting medications have a higher chance of developing tolerance and higher rates of overdose Our ceiling dose is 50mg of Morphine Equivalent Doses (MEDs) If patient is on a opioid OTHER than hydrocodone or morphine, please refer to our drug conversion chart and convert them over. 4. Should I prescribe short acting or long-acting opioids? According to CDC guidelines, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting opioids. There is a higher risk for overdose among patients initiating treatment with Extended Release (ER) / Long-Acting (LA) opioids Scheduled use of ER/ LA opioids does not seem to reduce risks for opioid misuse or addiction Time-scheduled opioid use can be associated with greater total average daily opioid dosage compared with intermittent, as-needed opioid use. There is currently not enough evidence to determine the safety of using immediate-release opioids for breakthrough pain when ER/ LA opioids are used for chronic pain (outside of active cancer pain / palliative care). This practice might be associated with unnecessary dose escalation. 5. Which opiates should I AVOID prescribing in the PCC? Avoid prescribing oxycodone, because: o It has more potency mg per mg, so it tends to be a more desired recreational drug o It has higher street value (for the above reason) o It is more likely to be falsely negative in the UDS, leading physicians to believe it is not being taken (when the patient actually may be adherent to the medication) Avoid use of codeine, because it has many PD450 interactions. Methadone or Fentanyl prescriptions are NOT recommended within the PCC o Methadone and Fentanyl have VERY long half-lives, so they can accumulate to toxic levels without very close follow-up o Methadone can prolong QTc and cause Sudden Cardiac Death 6

7 o Contact Chronic Pain Task Force with questions about management of patients who present to the PCC on these medications o Chronic methadone patients with heroine addiction should be managed by specialty methadone clinics. Consider referral to the below methadone clinics (keep in mind that methadone clinics ONLY distribute methadone for addiction, NOT pain): Southside Medical Center New Day Treatment Center Alliance Recovery Center Veterans Affairs Medical Center Substance Abuse Treatment Program 2685 Metropolitan Parkway, Suite C Atlanta, GA Martin Luther King Jr Drive Atlanta, GA Swanton Way, Suite B Decatur, GA Clairmont Road Decatur, GA (404) (404) (404) (404)

8 6. How should I follow-up with patients, after opiates have been initiated? Review the SPECIFIC functional goals that the patient has set (e.g. I want to walk two blocks to the grocery store) o Considering tapering off the opioid if no observed improvement in function Reassess patient s risk-benefit profile; continue opioids ONLY for low risk patients; taper off opioids if patient is at moderate or high risk: o Risk Level o Patient Characteristics o Low Risk o Moderate Risk o No history of substance use problem, past or current o No contributory family history of substance abuse o No major or untreated mental health problems o History of substance use problem (treated) o Family history of substance abuse o Comorbid minor or past major mental health problem o High Risk o Current substance use problem o Active addiction o Major untreated mental health problem Ensure mental health screening and treatment is provided, if appropriate: o If needing SSRI or SNRI, coach and encourage patient to stay on medication long enough for it to have time to work (>8-12 weeks at effective dose) (like a cast for a broken bone) o Give the option of calling Crisis hotline if they feel worse: o Consider referring to Dr. Tamara Haynes (board certified in BOTH Internal Medicine and Psychiatry) by sending her an EPIC message with MRN of patient Ensure alternative sources of pain control are being utilized: o PT/OT o Injection Clinic o Anesthesia s Procedure Clinic / Pain Clinic for possible injection: steroid injection; nerve block o Taper off opioids if the above adjunctive measures have been provided, but are not being utilized by patient 8

9 UDS ordered at follow-up clinic visit. If UDS positive for cocaine, benzodiazepines, amphetamines, then: The patient should not be prescribed additional opioids under any circumstances. Do NOT let patient manipulate the situation by saying they used illicit drugs "just one time." Do NOT re-prescribe opioids even if their follow up UDS is negative. The patient also should be referred for addiction services. This should ALL be documented clearly in the medical record. Check the GA prescription drug registry ( at EVERY visit to ensure patient has not filled any other opioid medications or benzodiazepines (if so, they cannot receive opioids from you).taper off opioids if: o Multiple opioid prescriptions have been filled at less-than-one month intervals o Opioid prescriptions filled at multiple different pharmacies in a short period of time o Opioid prescriptions written by doctors other than patient s PCP Ensure the patient has a follow-up appointment with YOU as their PCP at least within the next 90 days, but preferably within 30 days (okay to overbook if necessary to accomplish this). To prevent the patient from running out of medications before their next visit, may prescribe up to (but NO more than) a 90 day supply of medications. o Only do so if providing multiple prescriptions in this manner does not create an undue risk of diversion or abuse o Keep in mind that a three month refill should be written as three 3 separate monthly prescriptions (e.g. 1 st Rx is written as fill today, 2 nd Rx is written as do not fill until and 3 rd Rx is written as do not fill until 9

10 7. When should I escalate doses of opiates, and what is the ceiling dose? Recall that chronic opiate therapy will likely NOT cure a patient s pain, but may improve their function Make sure that patient has set SPECIFIC goals related to their function (e.g. I want to walk two blocks to the grocery store) o If function has not improved at all with current dose, advise patient that it likely will not improve with higher doses either o Could consider a short trial of higher dose, with EXPECTATION that you will taper off if no improvement in function (document this expectation in your clinic note) Recall that any opioid given chronically will become less effective (i.e. tolerance); this effect is not an indication of necessity to increase the opioid, but rather to continue to encourage more effective non-cot adjunctive therapies: o PT/OT o Pain clinic o Injection clinic o Acetaminophen/ NSAIDs o TCAs (if no cardiac history or prolonged QTc) Review patient s medication bottles to ensure they are on their current refill, and that the pill count is appropriate; if they are not taking the appropriate amount of their current regimen, no need to increase dose o If no pill bottles available for a pill count, call patient s pharmacy to review all active/recent medications Reassess patient s risk-benefit profile; ONLY increase opioids if patient is at low risk (if moderate or high risk, this would be an indication to taper the patient off): o Risk Level o Patient Characteristics o Low Risk o Moderate Risk o No history of substance use problem, past or current o No contributory family history of substance abuse o No major or untreated mental health problems o History of substance use problem (treated) o Family history of substance abuse o Comorbid minor or past major mental health problem 10

11 o Risk Level o High Risk o Patient Characteristics o Current substance use problem o Active addiction o Major untreated mental health problem Keep in mind that the ceiling dose for opiates in the PCC is 50mg of morphine-equivalent doses (MEDs) per 24 hours. See Review of ongoing COT for those already on doses exceeding the ceiling dosages, to taper them down. IF you feel that a patient requires dosage in excess of ceiling doses, then consult the Chronic Pain Task Force for review. 11

12 8. What should I do if I inherit a patient on chronic opiate therapy? Review indication for the medication and determine if appropriate: o Bursitis and Sleep disorders [including Fibromylagia] should not be treated with COT, but with appropriate specific treatments o Most cases of chronic LBP or sciatica should not be treated with COT Is the chronic pain ongoing? For example, if patient had chronic hip, but is now s/p THR, he/she should not need the same amount of opiates as prior to surgery; begin to taper Review utilization of other important adjunctive therapies: o PT/OT o If no PT/OT, educate patient on need for daily stretching to maintain/increase function over time o IF not increasing in flexibility; strongly consider weaning off COT If appropriate indication, but too high a dosage, consider: Tapering dosage over two weeks with initiation of other therapies (this choice is most appropriate for the majority of cases) Referral to Chronic Pain Faculty Task Force for recommendations Reassess patient s risk-benefit profile; taper off opioids if patient is at moderate or high risk: Risk Level Patient Characteristics Low Risk Moderate Risk No history of substance use problem, past or current No contributory family history of substance abuse No major or untreated mental health problems History of substance use problem (treated) Family history of substance abuse Comorbid minor or past major mental health problem High Risk Current substance use problem Active addiction Major untreated mental health problem 12

13 9. When should I taper a patient off opioids? COT should be tapered off for ANY of the following: Diversion if the patient has a negative UDS for a opioid which they are supposed to be taking Remember, UDS sensitive for hydrocodone Not as sensitive for oxycodone false negatives may occur If on oxycodone, convert to hydrocodone and reassess UDS after conversion Use of street drug (e.g. + UDS for cocaine) Benzodiazepine + on UDS Alteration of prescriptions (e.g. adding "0" to amount to be dispensed) Repeat failure of other aspects of chronic pain contract such as: o Not bringing all bottles for pill count; o Not coming to appointments; o Not making progress in PT; o Getting opiate prescriptions inappropriately from other doctors Abusive language, threats of physical violence, or physical violence will not be tolerated. Any patients exhibiting such behaviors during treatment should be weaned off opioid medications. 10. How do I taper a patient off opioids? A decrease by 10% of the original dose (both long-acting and/or short-acting simultaneously) per week is usually well tolerated with minimal physiological adverse effects. Some patients can be tapered more rapidly without problems (over 6 to 8 weeks). If any questions about how to taper, call the Chronic Pain Task Force. If opioid abstinence syndrome is encountered, it is rarely medically serious although symptoms may be unpleasant. Symptoms of an abstinence syndrome, such as nausea, diarrhea, muscle pain and myoclonus can be managed with: Clonidine mg orally every 6 hours, or Clonidine transdermal patch 0.1mg/24hrs (Cataprese TTS-1 ) weekly during the taper (while monitoring for often significant hypotension and anticholinergic side effects) In some patients it may be necessary to slow the taper timeline to monthly, rather than weekly dosage adjustments. 13

14 Symptoms of mild opioid withdrawal may persist for six months after opioids have been discontinued. Consider using adjuvant agents, such as antidepressants to manage irritability, sleep disturbance or antiepileptics for neuropathic pain. Referral for counseling or other support during this period is recommended if there are significant behavioral issues. Referral to a pain specialist or chemical dependency center should be made for complicated withdrawal symptoms. Remind patient that we (PCP and PCC) will not abandon them, but will continue to pursue other therapies Call patient s pharmacy to notify discontinuing all opioids Call Grady pharmacy to flag patient s medication list to avoid opioids Document the discontinuation in your progress note 14

15 11. If a patient has had opioids discontinued in the past, when and how should the PCP reinstitute chronic opiate therapy? After 3+ months of successful monthly follow-up of patient, showing o Active use of non-cot therapy, including improved flexibility with PT/OT stretches/exercises at home o Improvement in mental and social support spheres o Multiple repeat negative UDS examinations Obtain approval by Chronic Pain Faculty Task Force Review realistic goals of treatment, which are improvement in function RATHER than control of pain Ensure patient sets SPECIFIC functional goals (e.g. I want to be able to walk two blocks to the grocery store) Detailed discussion of points of chronic pain contract, see Appendix A UDS ordered and done, prior to initiating new prescriptions Review the Georgia Prescription Drug Registry ( to ensure no other opioid Rx s have been given 15

16 12. Under what circumstances can we give opioid medications for chronic pain during a walk-in (or non-pcp) visit in the PCC? IF patient is already a PCC continuity patient AND Has a current pain contract, AND In the last 3 months has been seen their PCP, AND Our system is preventing the patient from getting their agreed upon therapy (e.g. resident pulled from scheduled clinic or didn t give enough medication until next appointment) ***If all of the above criteria are met, okay to give enough opioid mediations to coordinate care until follow-up with PCP 13. Under what circumstances can we give benzodiazepines in the PCC? If patient is on a benzodiazepine, which was NOT started by their Grady PCP, then Refer patient back to the prescriber of the benzodiazepine IF after attempting to contact prescriber, and they are not available, then consider a ONE TIME, brief taper of benzodiazepine, but only if patient has all of the following: o Positive UDS for benzodiazepine o Stable home situation o NO concurrent alcohol abuse o NO suicidal ideations o Signed chronic pain medication agreement stating they understand: They are being tapered off this medication They will NOT continue similar medication from another provider They will NOT consume alcohol or illicit drugs Counsel on withdrawal symptoms; if symptoms noted go to ECC 16

17 14. If a patient is on a opioid that we do not provide in the PCC, how do I convert it to hydrocodone or morphine? Converting existing pain therapy to morphine or hydrocodone* I. Determine the total daily dose of the current pain medication. II. Using the conversion chart, determine the Morphine Milligram Equivalent (MME) dose by multiplying the dose of the current pain medication by the listed conversion factor. III. Decrease the MME dose by 50% to determine the starting dose of morphine or hydrocodone (to account for incomplete cross-tolerance and patient-specific differences in opioid pharmacokinetics). IV. Consider patient s renal function and drug interactions in regards to further dose adjustments. Current Opioid Conversion Factor to MME Codeine 0.15 Hydrocodone (IR) 1 Hydromorphone (IR or CR; not ER) 4 Morphine 1 Oxycodone 1.5 Oxymorphone 3 Adapted from Von Korff M, Saunders K, Ray GT, et al. Clin J Pain 2008;24:521 7 and Washington State Interagency Guideline on Prescribing Opioids for Pain ( *Dose conversions are for PO to PO formulations Examples: You are meeting a patient for the first time who has come to establish care. They are currently taking Percocet (oxycodone/acetaminophen) 5/325mg four times daily. What regimen utilizing hydrocodone would you convert them to (assuming the patient has normal renal and hepatic function)? 1. Total daily dose of oxycodone = 20 mg mg x 1.5 = 30 mg morphine = 30mg hydrocodone (since morphine and hydrocodone have a 1:1 conversion factor) mg/2 = 15 mg hydrocodone q 12 hours à new starting dose of hydrocodone (use hydrocodone/acetaminophen 5/325mg TID) 4. Note: hydrocodone and morphine are equivalent in potency; therefore, if you converted to morphine you would also start at a total daily dose of 15 mg Available dosage forms on the GRADY FORMULARY: Hydrocodone/acetaminophen tablets: 5/325mg Morphine sulfate (immediate-release) tablets: 15 mg, 30 mg 17

18 15. Who is on the Chronic Pain Task Force? Therese Vettese, MD, PIC Kristi Quairoli, Pharm D, PIC How do I approach the patient with a persistently negative UDS? Educate the patient that a negative UDS suggests they may not be taking the medications as prescribed Perform a pill count to determine that patient is not taking more medications per day than prescribed If on other types of opioids (e.g. oxycodone) switch to hydrocodone, as it is better detected in the UDS (refer to drug conversion table in this document) Give patient the expectation that if they have more than 3 negative UDS results, you will need to taper them off opioids (document this in your note) 18

19 17. What do I need to know about the Urine Drug Screen? We should order the UDS under the name Drug Screen-Pain Management. This ensures that the sample obtained is from the patient and has not been mistaken for a different patient. DRUG SCREEN PAIN MANAGEMENT [LAB3083] AMPHETAMINES BENZODIAZEPINES BARBITURATES COCAINE OPIATES PHENCYCLIDINE METHADONE METHAQUALONE PROPOXYPHENE FENTANYL Why is hydrocodone better detected in the UDS than oxycodone? o Our urine drug immunoassay screen has antibodies that detect morphine. A positive means the concentration has exceeded the 300 ng/ml morphine cutoff. o The antibody in our test reacts weakly with oxycodone (i.e. it takes an oxycodone urinary concentration of 2550 ng/ml to produce a positive signal). o Our UDS immunoassay is more sensitive for detecting hydrocodone; a concentration of about 250 ng/ml will trigger a positive result. Also, hydrocodone is metabolized to hydromorphone, which also reacts; a concentration of about 500 ng/ml produces a positive signal. Drug Detection and Elimination Times: Note: The data for detection times are estimates and vary by individual, dose, frequency of use, and metabolism. Sources: ARUP Laboratories Mayo Medical Laboratories 19

20 Amphetamine-Type Stimulants Limit of Quant (ng/ml) Detection Time (up to) Amphetamine 50 3 days Methamphetamine 50 3 days 3,4-Methylenedioxyamphetamine (MDA) 50 2 days 3,4-Methylenedioxymethamphetamine (MDMA) 50 2 days Phentermine 50 Ephedrine/pseudoephedrine Not quantitated 5 days Barbiturates Long-Acting Phenobarbital days Intermediate-Acting Butalbital days Amobarbital days Short-Acting Pentobarbital days Secobarbital days Benzodiazepines Long-Acting Diazepam 100 Nordiazepam 100 Intermediate-Acting Alprazolam 100 Lorazepam 100 Oxazepam 100 Temazepam 100 Chlordiazepoxide 100 Clonazepam 100 Flunitrazepam 50 Short-Acting Triazolam days 5 days 2 days 20

21 Flurazepam 100 Buprenorphine Limit of Quant (ng/ml) Detection Time (up to) Buprenorphine days Norbuprenorphine days Cocaine & Metabolite Cocaine 50 <1 day Benzoylecgonine 50 5 days Fentanyl Fentanyl days Norfentanyl 1 3 days Ketamine Ketamine 25 2 days Norketamine 25 2 days Lysergic Acid Diethylamide (LSD) LSD 0.5 <1 day 2-Oxo-3-hydroxy-LSD 5 5 days Marijuana/Cannabis (THC-COOH) Single Use 3 3 days Moderate Use (4 times per week) 5 days Heavy Use (daily) 10 days Chronic Heavy Use 30 days Methadone Methadone days EDDP (methadone metabolite) days 21

22 Methaqualone Methaqualone days Opiates 6-MAM day Morphine days Codeine days Hydrocodone days Hydromorphone days Oxycodone days Oxymorphone days Phencyclidine Phencyclidine 25 8 days Propoxyphene Propoxyphene days Norpropoxyphene days Questions: call the Grady Clinical Laboratory Customer Service Reference Laboratory Testing Laboratory Administration Dr. Dave Koch, Director, Clinical Chemistry & Toxicology After Hours Lab Supervisor

23 Patient/Caregiver s Name: Patient-Provider Chronic Pain Management Agreement Pt. MRN: Pt. Address: Phone Number: Primary Care Provider: Pharmacy Name: Pharmacy Number: I agree to follow these rules to be considered for opioid therapy. INITIALS (of patient to confirm understanding and agreement): Following My Doctor s Instruction for Medications and Other Treatments I will follow all of my doctor s instructions for taking medicines and for other treatments. I understand that it may take time to find the right type and amount of medicine to help decrease my pain. I will work with my doctor to find the right combination that limits my pain and helps me to function. I will use my medicines only as my doctor orders. I will not give or sell my medicines to other people. Doing My Daily Part and Keeping My Appointments I will do my part with frequent daily stretches and strengthening exercises. I will take my other medications which are part of my pain management. I will make and keep appointments for prescription re-fills. Getting My Opioid Prescriptions I will get opioids from my primary care doctor only, and only on the usual follow-up day. I will not ask for opioids from other doctors in the clinic, Emergency Room, or at other clinics or hospitals. I will fill my prescriptions at only one pharmacy (see above). Communicating / Coordinating Pain Management Medication Use If I do get opioid pain medicines from another doctor for a reason other than my chronic pain (for example, if I have an injury), I must let my primary care doctor know. I give permission for my doctor to independently look for and see my pain related medical records from other medical facilities/pharmacies to assure coordination of my pain management; my doctor must let me know if there are any problems found. By signing this form, I understand and agree to follow these rules. *** SEE Page 2 Signed (Patient/doctor): / Date: 23

24 Patient-Provider Chronic Pain Management Agreement Patient/Caregiver s Name: INITIALS (of patient to confirm understanding and agreement): I agree to follow these rules to be considered for opioid therapy. No Replacement Medicines I will be responsible for all prescriptions my doctor gives me. If I lose my prescription or if it is stolen, my doctor will not write another until my usual follow-up appointment. Bringing ALL Prescription Bottles to Monthly Appointments I will come to my usual clinic appointment every month unless my doctor says otherwise. I will bring ALL my recent prescription bottles with me for every visit. No Alcohol or Street Drugs I will not drink any alcohol (wine, beer or liquor) while I am taking this medicine. I understand that I cannot take any kind of street drug. I will not take other medications my doctor tells me not to take. At all visits, my doctor has the right to give blood or urine tests to check for drugs; I will come 1 hour early to clinic to have my urine checked before my appointment with my doctor. Broken agreement If I break this agreement, then I will not be able to receive opioids from the clinic. Examples of breaking this agreement include (but are not limited to): diverting medication (selling my medication or giving my medication to another person); using street drugs; repeatedly not keeping my appointments; not providing an appropriate urine/blood test on the day is was ordered; not actively trying all other therapies, including daily physical therapy, to help my pain. Communication with My Doctor if I can t function or if pain is too much I will let my doctor know if I cannot do what I need to do. I will let my doctor know if my pain is increasing. I know I can contact my doctor by leaving a message at this phone number: By signing this form, I understand and agree to follow these rules. ***SEE Page 1 Signed (Patient/doctor): / Date: 24

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions September 2016 HCMC Toxicology Transition: Additional information and Frequently Asked Questions Many clinicians have asked for more information about the Urine Drug Compliance Analysis (LAB8742) switch

More information

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date

More information

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D. Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

The Drug Testing Process. Employer or Practice

The Drug Testing Process. Employer or Practice Disclosures Clinical Professor, Jefferson Medical College BOD MROCC [Medical Review Officer Certification Council] BOD National Sleep Foundation BOD POEMS [Pennsylvania Occupational & Environmental Medicine

More information

Knock Out Opioid Abuse in New Jersey:

Knock Out Opioid Abuse in New Jersey: Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids

More information

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Frederick G. Strathmann, PhD, DABCC, (CC,TC) Medical Director, Toxicology Associate Scientific Director of MS ARUP Laboratories

More information

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J. Drug Adherence Assessment Report Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED PRESCRIPTION FLAG ANTICIPATED

More information

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter

More information

Subject: Pain Management (Page 1 of 7)

Subject: Pain Management (Page 1 of 7) Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all

More information

Laboratory Service Report

Laboratory Service Report 4 05/25/19 Client C702884-DLP ROCHESTER Amphetamines, Confirmation Positive Confirmed POSITIVE by LC-S/S for the following: Amphetamine = 52 ethamphetamine = 124 ethamphetamine exists in the d- and l-isomeric

More information

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G

More information

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG

More information

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching Liquid Chromatography Mass Spectrometry SSI-LCMS-8 LCMS-8 Drugs of Abuse: Analytes with Polarity Switching LCMS-8 Summary Seventy six analytes and their internal standards are described below. Multiple

More information

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) 1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory

More information

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine Pain Management Wrap-Up Chronic Care David Tauben, MD Medicine Anesthesia & Pain Medicine Objectives Understand that Pain is Complex Know how to select Rx based on Pain type Be aware that Rx only reduces

More information

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082 Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Test Definition: PCDSO Pain Clinic Drug Screen, Urine

Test Definition: PCDSO Pain Clinic Drug Screen, Urine Reporting Title: Pain Clinic Drug Screen, U Performing Location: Rochester Specimen Requirements: Collection Container/Tube: Plastic urine container Submission Container/Tube: Plastic, 60-mL urine bottle

More information

Physician s Reference for Urine and Blood Drug Testing and Interpretation

Physician s Reference for Urine and Blood Drug Testing and Interpretation Physician s Reference for Urine and Blood Drug Testing and Interpretation DETECTIMED PANEL Urine (test code 70195) Screen Confirmation Screen Confirmation Alcohol Ethanol Amphetamines Amphetamine Methamphetamine

More information

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine Reporting Title: Pain Clinic Drug Screen, CoC, U Performing Location: Rochester Specimen Requirements: Container/Tube: Chain-of-Custody Kit (Supply T282) containing the specimen containers, seals, and

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

Tapering Opioids Best Practices*

Tapering Opioids Best Practices* Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand

More information

Pain Medication Management Program Supports Patient Outcomes and Adherence

Pain Medication Management Program Supports Patient Outcomes and Adherence PeaceHealth Laboratories UPDATE 2015 Revised Edition Pain Medication Management Program Supports Patient Outcomes and Adherence BENEFITS Monitors analgesic medication adherence to ensure patient safety

More information

Pain Medication Management Program Monitors Patient Compliance

Pain Medication Management Program Monitors Patient Compliance PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018

Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018 Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018 Disclosures None Educational Objectives Understand CA state medical board guidelines for prescribing opioids for chronic pain Understand the

More information

Welcome - we will begin the webinar shortly Please read the participation tips below:

Welcome - we will begin the webinar shortly Please read the participation tips below: Welcome - we will begin the webinar shortly Please read the participation tips below: All guest phones have been muted: Background noises, conversations, white noise etc., can be disruptive to a webinar.

More information

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Adam S. Ptolemy 1, Colleen Murray 2, Edward Dunn 3,

More information

Patient-Centered Urine Drug Testing. Douglas Gourlay, MD, MSc, FRCPC, FASAM

Patient-Centered Urine Drug Testing. Douglas Gourlay, MD, MSc, FRCPC, FASAM Patient-Centered Urine Drug Testing Douglas Gourlay, MD, MSc, FRCPC, FASAM Declaration of Potential Conflict of Interest The content of this presentation is non- commercial and does not represent any conflict

More information

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY 2009 FINAL REPORT INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY This report was prepared by: Dr. Jose Arbelaez, M.D. of Baltimore Substance Abuse Systems, and Ryan J. Petteway,

More information

Conflict of Interest Disclosure

Conflict of Interest Disclosure Patient Rx Drug Misuse and Abuse: Compliance Toxicology Monitoring in Clinical Practice Toxicology Staff Andrea Terrell, Ph.D., DABCC Chief Scientific Officer George Behonick, Ph.D., DABFT, Manager, FBU

More information

Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies. 9/20/17

Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies.   9/20/17 You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies Jeffrey Fudin, BS, PharmD, FCCP, FASHP www.paindr.com Disclosures Astra Zeneca (Speakers Bureau) Collegium (Consultant) Daiichi

More information

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)? Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: HYDROMORPHONE (DILAUDID, EXALGO), CYCLOBENZAPRINE (FLEXERIL), METHADONE (METHADOSE),

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy

More information

2. Is this request for a preferred medication? Y N

2. Is this request for a preferred medication? Y N Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be

More information

Controlled Substance Monitoring in the Age of the Opioid Epidemic

Controlled Substance Monitoring in the Age of the Opioid Epidemic Controlled Substance Monitoring in the Age of the Opioid Epidemic Paul E. Hilliard, MS, MD Hospital Pain Committee Chair Department of Anesthesiology CME housekeeping I have no financial disclosures AKA,

More information

Chronic Pain Pharmacist role in the clinic

Chronic Pain Pharmacist role in the clinic Chronic Pain Pharmacist role in the clinic WSPA Annual Meeting 2015 Alvin Goo, PharmD Clinical Associate Professor University of Washington Schools of Pharmacy and Family Medicine Speakers Declaration

More information

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D.

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D. 1/25/17 PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D. PISA Physicians Kenneth B. Gossler M.D. Education University of Arizona Med School 1992. THMEP Intern 1993 Anesthesiology Residency at Financial

More information

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA Disclaimer

More information

Dr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force

Dr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force Dr. Smith Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force 1 1 How We Got Here 2 The Epidemic 3 4 San Diego Death Diaries

More information

Analgesics: Management of Pain In the Elderly Handout Package

Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed

More information

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY A report from the Office of Epidemiology and Planning Baltimore

More information

Urine drug testing it s not always crystal clear

Urine drug testing it s not always crystal clear Urine drug testing it s not always crystal clear Kirk Moberg, MD, PhD, FASAM Executive Medical Director, UnityPoint Health Illinois Institute for Addiction Recovery Clinical Professor of Internal Medicine

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK ccredited to Laboratory locations: Gavenny Court Brecon Road bergavenny Monmouthshire

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the

More information

Section I. Short-acting opioid Prior Authorization Criteria

Section I. Short-acting opioid Prior Authorization Criteria Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. Managing Narcotics on Workers Comp Claims Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. October 21, 2014 Outline Rationale Scope list drug list Recommended

More information

Strategies in Managing Opioid and Benzodiazepine Co-Prescribing

Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain Faculty Disclosure Henry C. Nipper, PhD, DABCC Dr. Nipper has listed no financial interest/arrangement that would be considered a conflict of interest. Urine Drug Testing to Monitor Opioid Use In Managing

More information

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital What Your Drug Test Really Means Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital Disclosure There are no relevant financial relationships with commercial interests associated.

More information

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation

More information

nextgen precision Test Report

nextgen precision Test Report nextgen precision TM Test Report SUMMARY OF PRECISION S NEXTGEN TEST REPORT In an effort to provide as much clinical insight as possible to our providers, we created our comprehensive NextGen Precision

More information

Pain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX

Pain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX Pain Management and Compliance Toxicology Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX Prescription Drug Abuse: A National Problem Prescription drug abuse is a growing

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016 Urine Drug Testing Methadone/Buprenorphine 101 Workshop Ron Joe, MD, DABAM December 10, 2016 Learning objectives Clarify the purpose of urine drug testing (UDT) Distinguish between UDT for detection of

More information

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation

More information

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Prior Authorization Guideline

Prior Authorization Guideline Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011

More information

Clinical contracts. Dr. Johan Wouterloot Prescribers Course April 28, 2017

Clinical contracts. Dr. Johan Wouterloot Prescribers Course April 28, 2017 Clinical contracts Dr. Johan Wouterloot Prescribers Course April 28, 2017 Why? Ameliorates power imbalance States a goal for the agreed upon activity Allows for contingency management to keep behaviour

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information

2013 Clinical drug and alcohol testing solutions. Product Catalog. CLIA-waived point of care test devices

2013 Clinical drug and alcohol testing solutions. Product Catalog. CLIA-waived point of care test devices 2013 Clinical drug and alcohol testing solutions Product Catalog CLIA-waived point of care test devices HELPING YOU MAKE INFORMED DECISIONS ABOUT ABUSE. Substance abuse testing with more substance. 2 of

More information

Fighting the Good Fight: How to Convert Opioids Just Right!

Fighting the Good Fight: How to Convert Opioids Just Right! Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,

More information

Gold Standard for Urine Drug Testin Urine Drug Testing Why U rine? Urine?

Gold Standard for Urine Drug Testin Urine Drug Testing Why U rine? Urine? Gold Standard for Urine Drug Testing Developed by TRMC Pain Management Center Jill Duffy, RN,BC Pam Kennell, RN, BC Heidi Beisch, RN Urine Drug Testing A DIAGNOSTIC tool For an OBJECTIVE test Based on

More information

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Safe Prescribing of Drugs with Potential for Misuse/Diversion College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines

More information

Legal Issues in Opioid Prescribing

Legal Issues in Opioid Prescribing Legal Issues in Opioid Prescribing Joanne L. Martin, J.D. Legal Counsel Mayo Clinic Rochester, Mn 2015 MFMER slide-1 Conflict of Interest I have no relevant financial relationships to disclose I will not

More information

Urine Opioid Dependency Panel (UODP) 1

Urine Opioid Dependency Panel (UODP) 1 Drug Testing Panels Urine Opioid Dependency Panel (UODP) 1 Amphetamines Amphetamine Methamphetamine Methylenedioxyamphetamine Adderall, Dexedrine, Vyvanse, Lisdexamfetamine (Speed, Bennies, Crystal Meth,

More information

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,

More information

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months

More information

Treatment Agreements Clinical Contracts. Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017

Treatment Agreements Clinical Contracts. Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017 Treatment Agreements Clinical Contracts Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017 Faculty/presenter disclosure Presenter: Dr. Paul Farnan Relationships

More information

Opioid Pain Contracts: A Resident Driven Quality Improvement Project

Opioid Pain Contracts: A Resident Driven Quality Improvement Project Opioid Pain Contracts: A Resident Driven Quality Improvement Project A Response to the Opioid Epidemic Dr. Phillip Knouse Dr. Victoria Montgomery Disclosure None Objectives Discuss the current Opioid Epidemic

More information

Walking the Line: Opioid Dose De-escalation

Walking the Line: Opioid Dose De-escalation Walking the Line: Opioid Dose De-escalation Courtney Kominek, PharmD, BCPS, CPE Disclosures Axial Healthcare Consultant Daiichi Sankyo Honoraria The views and opinions expressed in this presentation are

More information

DrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.

DrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc. Accuracy The accuracy of the DrugSmart Drugs of Abuse Tests was evaluated in comparison to commercially available drug screen tests. Sixty (60) negative urine samples collected from presumed non-user volunteers

More information

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

The Utility of Urine Drug Screening

The Utility of Urine Drug Screening The Utility of Urine Drug Screening Treating Addiction, Saving Lives Sea Cruises Bye Tazmania, still far from New Zealand February 8 th, 2018 Mandy Manak, MD FASAM, ISAM, CSAM, MRO Medical Director, ICDO

More information

Approaches to Responsible Opioid Prescribing. The Opioid Naïve Patient

Approaches to Responsible Opioid Prescribing. The Opioid Naïve Patient Approaches to Responsible Opioid Prescribing The Opioid Naïve Patient Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Prescription Drug Monitor Programs (PMDP): Combating prescription drug misuse and abuse. A physician s perspective.

Prescription Drug Monitor Programs (PMDP): Combating prescription drug misuse and abuse. A physician s perspective. Prescription Drug Monitor Programs (PMDP): Combating prescription drug misuse and abuse. A physician s perspective. Jeremy Johnson, MD UAB-Huntsville Family Medicine, Huntsville, AL Johnson Medical, LLC

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

Testing for Controlled Substances

Testing for Controlled Substances Testing for illicit drugs Testing for Controlled Substances 1 Purposes: Employment Sports Screening medical eval. Legal Monitoring Treatment Probation Prescribing controlled substances Forensics 2 Drug

More information

About Your Pain Management

About Your Pain Management UW MEDICINE PATIENT EDUCATION About Your Pain Management Answers to common questions This handout outlines the goals of pain management treatment. It also reviews the guidelines that you are expected to

More information

Shining a Light on MEDs Understanding morphine equivalent dose

Shining a Light on MEDs Understanding morphine equivalent dose Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

Opioid Prescribing Guidelines for Patients in the Emergency Department

Opioid Prescribing Guidelines for Patients in the Emergency Department Opioid Prescribing Guidelines for Patients in the Emergency Department and Immediate Care Centers These guidelines are meant to assist clinicians in treating patients with acute and chronic pain in the

More information

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19 Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Disclosures. Get Your Specimens in Order:

Disclosures. Get Your Specimens in Order: Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Jennifer Bolen, JD Disclosures Jennifer Bolen, JD Consultant to Generation Partners Consultant to Abbott

More information

URINE DRUG TOXICOLOGY

URINE DRUG TOXICOLOGY Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences URINE DRUG TOXICOLOGY Suzanne E. Rapp, MD GENERAL DISCLOSURES The University of Washington School of Medicine also

More information

Forensic Toxicology Scope of Testing and Detection Limits

Forensic Toxicology Scope of Testing and Detection Limits Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES... 2 Volatile Screen by GC/FID... 2 Carbon Monoxide by Microdiffusion... 2 Ethylene Glycol by GC/MS... 2

More information

Drugs of Abuse I Serum

Drugs of Abuse I Serum Drugs of Abuse I Serum 2017-11 1.10 For quality monitoring of quantitative measurements by chromatographic methods These reference materials are produced on the basis of human matrices. The highly accurate

More information

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18 Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

For female patients only: To the best of my knowledgei am NOT pregnant. Patients Initials:

For female patients only: To the best of my knowledgei am NOT pregnant. Patients Initials: Which doctor are you here to see? NAME OF PATIENT: DATE: TO THE PATIENT: As a patient, you have the right to be informed about your condition and the recommended medical or diagnostic procedure or drug

More information

Managed Care Pushes for Safer Opioid Oversight

Managed Care Pushes for Safer Opioid Oversight Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging

More information

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD) Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure

More information

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Opioid Analgesics. Recommended starting dose for opioid-naïve patients Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote

More information